NCT06628687View on ClinicalTrials.gov

A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it During Pregnancy and/or During Breastfeeding and About the Health of Their Babies

RecruitingOBSERVATIONAL
Enrollment

20

Participants

Timeline

Start Date

October 26, 2026

Primary Completion Date

April 30, 2035

Study Completion Date

April 30, 2035

Conditions
Friedreich Ataxia
Interventions
DRUG

Omaveloxolone

Administered as specified in the treatment arm.

Trial Locations (1)

27560

RECRUITING

Evidera, Morrisville

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY

NCT06628687 - A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it During Pregnancy and/or During Breastfeeding and About the Health of Their Babies | Biotech Hunter | Biotech Hunter